Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $688,725.00 in Stock

05 Oct 2026, 08:54 by Danessa Lincoln · The Markets Daily

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CFO Scott Burrows sold 7,500 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $91.83, for a total transaction of $688,725.00. Following the sale, the chief financial officer owned 79,762 shares of the company’s stock, valued at $7,324,544.46. This trade represents a 8.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Stock Performance

Spyre Therapeutics stock opened at $93.19 on Monday. The business’s 50-day simple moving average is $95.71 and its 200-day simple moving average is $81.70. The firm has a market capitalization of $8.20 billion, a PE ratio of -47.79 and a beta of 3.10. Spyre Therapeutics, Inc. has a 52 week low of $15.86 and a 52 week high of $110.18.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.40. Research analysts forecast that Spyre Therapeutics, Inc. will post -2.71 earnings per share for the current year.

Wall Street Analyst Weigh In

SYRE has been the topic of a number of research reports. Wolfe Research lowered shares of Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, July 28th. Wedbush restated an “outperform” rating and issued a $123.00 price target on shares of Spyre Therapeutics in a research report on Wednesday, September 9th. BTIG Research restated a “buy” rating and set a $121.00 price objective on shares of Spyre Therapeutics in a report on Thursday. JPMorgan Chase & Co. assumed coverage on shares of Spyre Therapeutics in a research report on Thursday. They set an “overweight” rating and a $110.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Spyre Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $109.71.

Get Our Latest Analysis on SYRE

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC increased its holdings in Spyre Therapeutics by 23.3% in the 1st quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company’s stock valued at $190,826,000 after buying an additional 714,000 shares during the period. Capital International Investors lifted its holdings in shares of Spyre Therapeutics by 46.0% during the 4th quarter. Capital International Investors now owns 3,492,541 shares of the company’s stock worth $114,416,000 after acquiring an additional 1,100,000 shares during the period. Commodore Capital LP lifted its holdings in shares of Spyre Therapeutics by 20.1% during the 4th quarter. Commodore Capital LP now owns 2,388,245 shares of the company’s stock worth $78,239,000 after acquiring an additional 400,161 shares during the period. Bank of America Corp DE boosted its position in shares of Spyre Therapeutics by 192.6% during the 1st quarter. Bank of America Corp DE now owns 1,228,093 shares of the company’s stock valued at $61,945,000 after acquiring an additional 808,366 shares in the last quarter. Finally, Candriam S.C.A. boosted its position in shares of Spyre Therapeutics by 43.4% during the 1st quarter. Candriam S.C.A. now owns 610,282 shares of the company’s stock valued at $30,783,000 after acquiring an additional 184,748 shares in the last quarter. 80.39% of the stock is owned by institutional investors.

Trending Headlines about Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

Positive Sentiment: Analyst support strengthened: BTIG Research reaffirmed its “buy” rating and assigned a $121 price target, while JPMorgan initiated coverage with an “overweight” rating and a $110 target. The recommendations imply meaningful potential upside from recent trading levels and provide positive validation for Spyre’s immunology pipeline. BTIG Research rating report
Neutral Sentiment: Employee inducement awards announced: Spyre granted two new employees options covering 21,424 shares and 6,604 restricted stock units. The awards were required to support hiring and are not directly related to clinical or financial results, although they could modestly increase future share dilution. Spyre Therapeutics inducement awards announcement
Negative Sentiment: Multiple insiders sold shares: CEO Cameron Turtle sold 15,000 shares, CFO Scott Burrows sold a combined 25,000 shares, and insider Heidy King-Jones sold 28,933 shares. The transactions represent notable reductions in ownership, particularly King-Jones’s roughly 91% decrease, which may raise caution about insider sentiment. However, all sales were executed under pre-arranged Rule 10b5-1 trading plans, reducing their significance as discretionary signals of declining confidence. Spyre insider trading filing

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.